Evidence map›Paper›PMID 32666165›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2020

Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study.

Harold W de Valk, Michael Feher, Troels Krarup Hansen, Johan Jendle, Mette Marie Koefoed, Ehsan Parvaresh Rizi, Esther Zimmermann, Gian Paolo Fadini

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02392117 (A Multi-centre, Prospective, Non-interventional Study of Insulin Degludec Investigating the Safety and Effectiveness in a Real World Population With Type 1 and 2 Diabetes Mellitus), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02392117 completednot on this map

A Multi-centre, Prospective, Non-interventional Study of Insulin Degludec Investigating the Safety and Effectiveness in a Real World Population With Type 1 and 2 Diabetes Mellitus

TypeobservationalSponsorNovo Nordisk A/SRan2015 to 2018Enrolled1,262ConditionsDiabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2Armsinsulin degludec
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 5 countries.

Harold W de ValkDepartment of Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. H.W.deValk@umcutrecht.nl.ORCID http://orcid.org/0000-0002-8565-0939
Michael FeherBeta Cell Diabetes Centre, Chelsea and Westminster Hospital, London, UK.
Troels Krarup HansenSteno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Johan JendleFaculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.
Mette Marie KoefoedNovo Nordisk A/S, Søborg, Denmark.
Ehsan Parvaresh RiziNovo Nordisk A/S, Søborg, Denmark.
Esther ZimmermannNovo Nordisk A/S, Søborg, Denmark.
Gian Paolo FadiniDepartment of Medicine, Division of Metabolic Diseases, University of Padova, Padova, Italy.
Novo Nordisk (Denmark) · DKÖrebro University · SESteno Diabetes Centers · DKUniversity Medical Center Utrecht · NLUniversity of Padua · ITUniversity of Surrey · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHypoglycaemia is a common side effect of insulin therapy; low or high glycated haemoglobin (HbA

methodsThe ReFLeCT study was a prospective observational study over 12 months. Patient-reported diary data on hypoglycaemia were collected from patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) who were switching from other basal insulins to insulin degludec (degludec) at their physician's discretion in routine clinical care. Two secondary analyses were undertaken to investigate the change in number of hypoglycaemic events: a post hoc analysis using the updated American Diabetes Association (ADA) level 1, 2 and 3 hypoglycaemia definitions, and a pre-specified analysis using patient characteristics (baseline HbA

resultsSwitching to degludec was associated with significantly fewer hypoglycaemic events for all definitions in T1D, and level 1 and 2 in T2D (too few level 3 events for statistical comparison). Moreover, patient characteristics did not influence the observed reduction in hypoglycaemia in T1D and T2D.

conclusionThese results demonstrate that switching to degludec from other basal insulins was associated with reduced rates of hypoglycaemia, irrespective of the definition used or baseline patient characteristics.

trial registrationNCT02392117.

Indexed as

Basal insulinHypoglycaemiaInsulin degludecType 1 diabetesType 2 diabetes

Identifiers

PMID32666165
PMCPMC7434826
OpenAlexW3043664475

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.